Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion
- PMID: 18644063
- DOI: 10.1111/j.1464-5491.2008.02486.x
Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion
Abstract
Aims: Continuous subcutaneous insulin infusion (CSII) is a recommended treatment for reducing severe hypoglycaemia in Type 1 diabetes, but the change in hypoglycaemia compared with multiple daily insulin injections (MDI) is unclear. We therefore conducted a meta-analysis comparing severe hypoglycaemia and glycaemic control during CSII and MDI.
Methods: Databases and literature (1996-2006) were searched for randomized controlled trials (RCTs) and before/after studies of > or = 6 months' duration CSII and with severe hypoglycaemia frequency > 10 episodes/100 patient years on MDI.
Results: In 22 studies (21 reports), severe hypoglycaemia during MDI was related to diabetes duration (P = 0.038) and was greater in adults than children (100 vs. 36 events/100 patient years, P = 0.036). Severe hypoglycaemia was reduced during CSII compared with MDI, with a rate ratio of 2.89 (95% CI 1.45 to 5.76) for RCTs and 4.34 (2.87 to 6.56) for before/after studies [rate ratio 4.19 (2.86 to 6.13) for all studies]. The reduction was greatest in those with the highest initial severe hypoglycaemia rates on MDI (P < 0.001). The mean difference in glycated haemoglobin (HbA(1c)) between treatments was less for RCTs [0.21% (0.13-0.30%)] than in before/after studies [0.72% (0.55-0.90%)] but strongly related to the initial HbA(1c) on MDI (P < 0.001).
Conclusions: The severe hypoglycaemia rate in Type 1 diabetes was markedly less during CSII than MDI, with the greatest reduction in those with most severe hypoglycaemia on MDI and those with the longest duration of diabetes. The biggest improvement in HbA(1c) was in those with the highest HbA(1c) on MDI.
Comment in
-
Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion.Diabet Med. 2009 Mar;26(3):311-2; author reply 312-3. doi: 10.1111/j.1464-5491.2009.02668.x. Diabet Med. 2009. PMID: 19317829 No abstract available.
Similar articles
-
In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.Diabet Med. 2008 Mar;25(3):326-32. doi: 10.1111/j.1464-5491.2007.02365.x. Diabet Med. 2008. PMID: 18307459 Clinical Trial.
-
Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections.Diabet Med. 2008 Feb;25(2):213-20. doi: 10.1111/j.1464-5491.2007.02346.x. Epub 2008 Jan 14. Diabet Med. 2008. PMID: 18201210
-
Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.Diabet Med. 2006 Aug;23(8):900-6. doi: 10.1111/j.1464-5491.2006.01935.x. Diabet Med. 2006. PMID: 16911629
-
Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy.Diabetes Metab Res Rev. 2009 Feb;25(2):99-111. doi: 10.1002/dmrr.931. Diabetes Metab Res Rev. 2009. PMID: 19172576 Review.
-
Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.Diabetologia. 2008 Jun;51(6):941-51. doi: 10.1007/s00125-008-0974-3. Epub 2008 Mar 20. Diabetologia. 2008. PMID: 18351320 Review.
Cited by
-
Therapeutic Insulin Analogue Concentrations at Infusion Sites Enhanced the Pro-Inflammatory Response and Apoptosis in an In Vitro Macrophage-Material Interaction Model.ACS Pharmacol Transl Sci. 2024 Jul 3;7(8):2544-2556. doi: 10.1021/acsptsci.4c00363. eCollection 2024 Aug 9. ACS Pharmacol Transl Sci. 2024. PMID: 39156741
-
2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association.Diabetes Metab J. 2024 Jul;48(4):546-708. doi: 10.4093/dmj.2024.0249. Epub 2024 Jul 26. Diabetes Metab J. 2024. PMID: 39091005 Free PMC article. No abstract available.
-
Safety and Psychological Outcomes of Tandem t:Slim X2 Insulin Pump with Control-IQ Technology in Children, Adolescents, and Young Adults with Type 1 Diabetes: A Systematic Review.Diabetes Ther. 2024 Oct;15(10):2133-2149. doi: 10.1007/s13300-024-01618-2. Epub 2024 Jul 15. Diabetes Ther. 2024. PMID: 39008237 Free PMC article. Review.
-
Continuous subcutaneous insulin infusion versus multiple daily injection therapy in pregnant women with type 1 diabetes.J Diabetes. 2024 May;16(5):e13558. doi: 10.1111/1753-0407.13558. J Diabetes. 2024. PMID: 38664886 Free PMC article.
-
A Three-Arm Randomized Controlled Study Comparing Patient-Reported Outcomes in People With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion or Multiple Daily Injections.J Diabetes Sci Technol. 2024 Mar 8:19322968241234055. doi: 10.1177/19322968241234055. Online ahead of print. J Diabetes Sci Technol. 2024. PMID: 38456441 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous